Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

445 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Serum very long-chain fatty acid-containing lipids predict response to immune checkpoint inhibitors in urological cancers.
Mock A, Zschäbitz S, Kirsten R, Scheffler M, Wolf B, Herold-Mende C, Kramer R, Busch E, Jenzer M, Jäger D, Grüllich C. Mock A, et al. Among authors: scheffler m. Cancer Immunol Immunother. 2019 Dec;68(12):2005-2014. doi: 10.1007/s00262-019-02428-3. Epub 2019 Nov 7. Cancer Immunol Immunother. 2019. PMID: 31701161 Free PMC article.
A plasma metabolite panel as biomarkers for early primary breast cancer detection.
Yuan B, Schafferer S, Tang Q, Scheffler M, Nees J, Heil J, Schott S, Golatta M, Wallwiener M, Sohn C, Koal T, Wolf B, Schneeweiß A, Burwinkel B. Yuan B, et al. Among authors: scheffler m. Int J Cancer. 2019 Jun 1;144(11):2833-2842. doi: 10.1002/ijc.31996. Epub 2019 Jan 4. Int J Cancer. 2019. PMID: 30426507
Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.
Chudasama P, Renner M, Straub M, Mughal SS, Hutter B, Kosaloglu Z, Schweßinger R, Scheffler M, Alldinger I, Schimmack S, Persigehl T, Kobe C, Jäger D, von Kalle C, Schirmacher P, Beckhaus MK, Wolf S, Heining C, Gröschel S, Wolf J, Brors B, Weichert W, Glimm H, Scholl C, Mechtersheimer G, Specht K, Fröhling S. Chudasama P, et al. Among authors: scheffler m. Clin Cancer Res. 2017 Feb 15;23(4):962-973. doi: 10.1158/1078-0432.CCR-16-0860. Epub 2016 Aug 17. Clin Cancer Res. 2017. PMID: 27535980
Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening.
Häusler SF, Keller A, Chandran PA, Ziegler K, Zipp K, Heuer S, Krockenberger M, Engel JB, Hönig A, Scheffler M, Dietl J, Wischhusen J. Häusler SF, et al. Among authors: scheffler m. Br J Cancer. 2010 Aug 24;103(5):693-700. doi: 10.1038/sj.bjc.6605833. Epub 2010 Aug 3. Br J Cancer. 2010. PMID: 20683447 Free PMC article.
Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient.
Scheffler M, Merkelbach-Bruse S, Bos M, Fassunke J, Gardizi M, Michels S, Groneck L, Schultheis AM, Malchers F, Leenders F, Kobe C, König K, Heukamp LC, Sos ML, Thomas RK, Büttner R, Wolf J. Scheffler M, et al. J Thorac Oncol. 2015 Jun;10(6):e40-3. doi: 10.1097/JTO.0000000000000503. J Thorac Oncol. 2015. PMID: 26001148 Free article. No abstract available.
Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors.
Ortiz-Cuaran S, Scheffler M, Plenker D, Dahmen L, Scheel AH, Fernandez-Cuesta L, Meder L, Lovly CM, Persigehl T, Merkelbach-Bruse S, Bos M, Michels S, Fischer R, Albus K, König K, Schildhaus HU, Fassunke J, Ihle MA, Pasternack H, Heydt C, Becker C, Altmüller J, Ji H, Müller C, Florin A, Heuckmann JM, Nuernberg P, Ansén S, Heukamp LC, Berg J, Pao W, Peifer M, Buettner R, Wolf J, Thomas RK, Sos ML. Ortiz-Cuaran S, et al. Among authors: scheffler m. Clin Cancer Res. 2016 Oct 1;22(19):4837-4847. doi: 10.1158/1078-0432.CCR-15-1915. Epub 2016 Jun 1. Clin Cancer Res. 2016. PMID: 27252416
Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients.
König K, Peifer M, Fassunke J, Ihle MA, Künstlinger H, Heydt C, Stamm K, Ueckeroth F, Vollbrecht C, Bos M, Gardizi M, Scheffler M, Nogova L, Leenders F, Albus K, Meder L, Becker K, Florin A, Rommerscheidt-Fuss U, Altmüller J, Kloth M, Nürnberg P, Henkel T, Bikár SE, Sos ML, Geese WJ, Strauss L, Ko YD, Gerigk U, Odenthal M, Zander T, Wolf J, Merkelbach-Bruse S, Buettner R, Heukamp LC. König K, et al. Among authors: scheffler m. J Thorac Oncol. 2015 Jul;10(7):1049-57. doi: 10.1097/JTO.0000000000000570. J Thorac Oncol. 2015. PMID: 26102443 Free article.
Clinical and Pathological Characteristics of KEAP1- and NFE2L2-Mutated Non-Small Cell Lung Carcinoma (NSCLC).
Frank R, Scheffler M, Merkelbach-Bruse S, Ihle MA, Kron A, Rauer M, Ueckeroth F, König K, Michels S, Fischer R, Eisert A, Fassunke J, Heydt C, Serke M, Ko YD, Gerigk U, Geist T, Kaminsky B, Heukamp LC, Clement-Ziza M, Büttner R, Wolf J. Frank R, et al. Among authors: scheffler m. Clin Cancer Res. 2018 Jul 1;24(13):3087-3096. doi: 10.1158/1078-0432.CCR-17-3416. Epub 2018 Apr 3. Clin Cancer Res. 2018. PMID: 29615460
Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma.
Riedel R, Michels S, Heydt C, Siemanowski J, Kobe C, Bunck A, Schäfer S, Fischer RN, Scheffler M, Abdulla DSY, Nogová L, Koleczko S, Merkelbach-Bruse S, Büttner R, Wolf J. Riedel R, et al. Among authors: scheffler m. Lung Cancer. 2019 Jul;133:20-22. doi: 10.1016/j.lungcan.2019.05.006. Epub 2019 May 6. Lung Cancer. 2019. PMID: 31200822
445 results